An improved nitroblue tetrazolium test using phorbol myristate acetate-coated coverslips.
The endotoxin--nitroblue tetrazolium (NBT) slide test was modified by precoating coverslips with phorbol myristate acetate instead of endotoxin. The percentage of control polymorphonuclear leukocytes reducing NBT was significantly (P less than .05) greater on phorbol myristate acetate-coated coverslips (99 +/- 0.21%) than on endotoxin-coated coverslips (96+/- 1.8%). Polymorphonuclear leukocytes from patients with chronic granulomatous disease did not reduce NBT on phorbol myristate acetate- or endotoxin-treated coverslips. NBT reduction by polymorphonuclear leukocytes from proven heterozygotic carriers of sex-linked chronic granulomatous disease was intermediate between NBT reductions by those from controls and patients. A statistically significant abnormality of NBT reduction was found in polymorphonuclear leukocytes from one carrier of chronic granulomatous disease with phorbol myristate acetate-treated, but not endotoxin-treated coverslips. The phorbol myristate acetate-NBT coverslip technic is a rapid, simple, reliable way to detect deficiencies in polymorphonuclear leukocytes from patients and carriers of chronic granulomatous disease.
D055598:Chemical Phenomena; D002621:Chemistry; D006105:Granulomatous Disease, Chronic / Q000235:genetics / Q000473:pathology; D006579:Heterozygote; D006801:Humans; D009504:Neutrophils / Q000032:analysis* / Q000166:cytology; D009580:Nitroblue Tetrazolium; D010704:Phorbols; D013755:Tetradecanoylphorbol Acetate; D013778:Tetrazolium Salts
D010704:Phorbols; D013778:Tetrazolium Salts; D009580:Nitroblue Tetrazolium; D013755:Tetradecanoylphorbol Acetate